Ameritas Investment Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-3,728
Closed -$56K 3066
2022
Q3
$56K Buy
3,728
+622
+20% +$7.23K ﹤0.01% 1895
2022
Q2
$23K Hold
3,106
﹤0.01% 2500
2022
Q1
$28K Hold
3,106
﹤0.01% 2412
2021
Q4
$22K Hold
3,106
﹤0.01% 2613
2021
Q3
$35K Hold
3,106
﹤0.01% 2387
2021
Q2
$50K Hold
3,106
﹤0.01% 2193
2021
Q1
$56K Sell
3,106
-500
-14% -$8.64K ﹤0.01% 2023
2020
Q4
$49K Hold
3,606
﹤0.01% 2008
2020
Q3
$42K Hold
3,606
﹤0.01% 1948
2020
Q2
$53K Hold
3,606
﹤0.01% 1793
2020
Q1
$49K Hold
3,606
﹤0.01% 1678
2019
Q4
$87K Hold
3,606
﹤0.01% 1600
2019
Q3
$69K Hold
3,606
﹤0.01% 1689
2019
Q2
$107K Buy
3,606
+642
+22% +$24.7K ﹤0.01% 1464
2019
Q1
$141K Hold
2,964
0.01% 1251
2018
Q4
$107K Hold
2,964
0.01% 1328
2018
Q3
$182K Hold
2,964
0.01% 1147
2018
Q2
$200K Buy
2,964
+159
+6% +$8.9K 0.01% 1068
2018
Q1
$152K Hold
2,805
0.01% 1233
2017
Q4
$168K Buy
2,805
+140
+5% +$8.49K 0.01% 1182
2017
Q3
$152K Hold
2,665
0.01% 1215
2017
Q2
$140K Buy
2,665
+275
+12% +$12.8K 0.01% 1256
2017
Q1
$108K Buy
+2,390
New +$107K 0.01% 1385

Ameritas Investment Partners's AERI Position: Q4 2022 in Review

Ameritas Investment Partners sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 3,728 shares — an estimated $56K sold.

Ameritas Investment Partners first reported a position in AERI in Q1 2017 and held it in 23 quarters. The position peaked at $200K in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Ameritas Investment Partners reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 3,728 Aerie Pharmaceuticals shares in Q4 2022, an estimated $56K.
  • Ameritas Investment Partners first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 23 quarters.
  • Ameritas Investment Partners's Aerie Pharmaceuticals position peaked at $200K in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Ameritas Investment Partners's 13F filing for Q4 2022, filed 13 Feb 2023.